CPRX merger endgame: what the July 14 halt and USD 31.50 cash deal mean for options

Catalyst Pharmaceuticals has moved into the final market phase of its sale to Angelini Pharma. Nasdaq now says July 14, 2026 is the anticipated last trading day for CPRX, that the stock is expected to be halted after the after-hours session at around 7:50 p.m. ET on July 14, that the merger is tentatively scheduled to close before the market open on July 15, and that suspension would be effective July 16 if the transaction closes as planned.

For options traders, that changes the question materially. CPRX is no longer mainly a rare-disease commercial story with acquisition optionality in the background. It is a final-session cash-deal setup where residual time value, assignment discipline, and the gap between a stock-trading notice and the later OCC end-state memo matter more than any fresh view on Firdapse, Agamree, or the company’s stand-alone growth plan.

This article is for market commentary and options education only. It is not financial advice, investment advice, trading advice, or a recommendation to buy or sell any security or options contract. Options trading involves risk and is not suitable for all investors. Review the site’s risk disclosure.

What changed in the endgame phase

Catalyst’s deal with Angelini was announced in early May, and stockholders approved it on July 8. Nasdaq’s merger alert is what pushes the setup into a more actionable options phase:

That may sound straightforward, but it matters because this is where merger names stop being mostly about whether the acquisition is attractive and start being mostly about contract handling. The market already knows the broad price and strategic story. What it needs to process now is the timing of the final live session and how quickly the remaining option premium can collapse into mostly intrinsic value.

Why This Matters For Options Traders

1. The setup has shifted from biotechnology narrative to merger mechanics

Earlier in the transaction, a trader could still talk about Catalyst through product growth, patent settlement headlines, or the strategic value of a U.S. commercial platform to Angelini. Once Nasdaq sets an anticipated last trading day and halt path, that framing becomes less important for listed options.

At this stage, the practical issue is whether CPRX options still carry meaningful residual extrinsic value before the halt and how traders handle the final session. That is a very different problem from asking whether Angelini is paying a fair price or whether Catalyst could have grown independently.

2. A stock halt notice is not the same thing as the final OCC memo

This is the most important distinction to keep clear. Nasdaq’s corporate-actions alert tells traders how the stock is expected to stop trading. It does not, by itself, finalize the listed-options deliverable, expiration handling, or any acceleration framework.

In many cash mergers, traders expect options eventually to move toward a cash-only settlement logic. That expectation can be directionally useful, but it is still not a substitute for the official OCC contract-adjustment notice. Until that memo appears, traders should avoid treating assumptions as settled terms.

That is exactly why pages such as cash-settled vs physically-settled options explained, options expiration, assignment, and exercise explained, and early assignment risk in options trading: when and why it happens are useful in this phase. They explain the mechanics traders often think they remember until a merger name forces them to check the details.

3. Residual assignment risk still exists into the halt window

One of the most common mistakes in late-stage cash deals is assuming assignment risk has effectively vanished because the stock is “basically done.” That is not how listed options work. If there is still enough incentive to exercise before the halt, a short option can still become an assignment problem.

The core lesson is simple: a near-fixed stock price does not make the remaining option position trivial. Thin extrinsic value, narrowing time, and a known end-of-trading window can all make exercise economics more sensitive, not less.

4. Index and ownership changes can affect interpretation, even if they do not set the option terms

The broader transaction context also matters. Catalyst’s merger documentation and related coverage point to delisting and index removal once the transaction closes. That is not the same as an options adjustment memo, but it does reinforce that the security is being pushed through an end-state transition rather than continuing as a normal operating-company stock.

That matters for one reason: traders should not expect the usual post-earnings or post-news equilibrium behavior from the stock or the chain. A final-session merger name can look calm on the surface while still being awkward to trade because the market is effectively pricing the mechanics of disappearance.

5. Liquidity and execution often matter more than directional conviction

By this stage of a cash merger, many traders are not being paid for a fresh insight into the business. They are mostly exposed to execution quality, timing, and contract interpretation. Wide spreads can matter more than thesis. Time decay can matter more than narrative. A small misunderstanding about the end-state process can matter more than whether you were “right” about the company months ago.

That is why traders who want to learn from these names should think in terms of process. What exactly is confirmed today? What is still pending from OCC? How much extrinsic value remains? What is the assignment exposure? Those questions are more valuable than any generic view that the deal is “safe.”

What is confirmed, and what is still open

Confirmed facts

• Nasdaq says the merger was approved by Catalyst stockholders and is tentatively scheduled to close before the market open on July 15, 2026.
• Nasdaq says July 14, 2026 is the anticipated last trading day for CPRX.
• Nasdaq says the stock is expected to be halted after the after-hours session at around 7:50 p.m. ET on July 14.
• Nasdaq says marketplace suspension would be effective July 16, 2026 if the merger closes as anticipated.
• Nasdaq says the merger consideration is USD 31.50 in cash per share.

Interpretation

• CPRX options should now be treated as a final-session cash-deal instrument rather than a normal biotech catalyst trade.
• The main trader value has shifted from acquisition speculation into contract-handling discipline.
• Time value can continue compressing quickly as the market approaches the halt window.

Still open

• Nasdaq’s alert does not replace the final OCC contract-adjustment memo.
• The precise options end-state should not be treated as fully confirmed until OCC publishes it.
• The closing path is still described as anticipated, which means timing changes remain a practical risk until the transaction is actually closed.

Why this is a distinct event phase

This is not just a repeat of the May 7 acquisition announcement. The May phase was about the deal premium, Angelini’s U.S. expansion strategy, and whether shareholders were likely to approve the transaction. The July 14 phase is about how a listed options market behaves when the underlying stock is about to stop trading.

That is a different educational lesson for self-directed options traders. One phase is about repricing from a headline. The later phase is about end-state mechanics: how intrinsic value dominates, how assignment risk can still matter, and how final stock-trading milestones differ from final options-contract milestones.

What Traders May Misunderstand

“USD 31.50 cash means the option chain cannot surprise me”

Wrong. The stock consideration may be simple, but the contract-adjustment path still comes from OCC. Traders can still be surprised if they assume the final deliverable or expiration handling before it is officially published.

“The stock is basically pinned, so assignment no longer matters”

Also wrong. Assignment risk depends on contract economics, residual extrinsic value, and timing, not on whether the story feels boring.

“A Nasdaq halt notice already tells me the final options terms”

No. Nasdaq governs the stock-trading path. OCC governs listed-option contract mechanics. Those processes are connected, but they are not the same notice.

“This is just another biotech M&A article”

Not at this stage. The interesting part now is not drug development or strategic fit. It is the final-session behavior of a cash-deal option chain.

Bottom line

Catalyst has entered the late mechanical phase of its sale to Angelini. Nasdaq now points to July 14, 2026 as the anticipated last trading day, an after-hours halt around 7:50 p.m. ET that same day, a July 15 closing path before the open, and July 16 suspension if the deal closes on schedule. The stated stockholder consideration remains USD 31.50 in cash per share.

For options traders, that turns CPRX into a final-session contract-management story. The durable lesson is not about calling the business. It is about understanding the difference between stock-trading milestones and OCC option-adjustment milestones, recognizing that residual assignment risk can survive much longer than many traders assume, and treating late-stage merger options as execution-sensitive instruments rather than easy cash-proxy bets.

This article is not financial, investment, or trading advice. Options involve substantial risk, including event timing risk, assignment risk, liquidity risk, and losses that can exceed what a trader initially expects.

Sources

• Nasdaq Trader Corporate Actions Alert #2026-485, July 9, 2026: https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-485
• Catalyst Pharmaceuticals and Angelini Pharma joint announcement, May 7, 2026: https://ir.catalystpharma.com/news/news-details/2026/Angelini-Pharma-to-Acquire-Catalyst-Pharmaceuticals-for-4-1-Billion-USD-3-5-Billion-Euros-Entering-the-U-S--Market-and-Consolidating-its-Leadership-in-Brain-Health-and-Rare-Disease-3e9bed681/default.aspx
• SEC Form 8-K filed by Catalyst Pharmaceuticals, May 7, 2026: https://www.sec.gov/Archives/edgar/data/1369568/000119312526210518/d90722d8k.htm
• SEC Form 8-K filed by Catalyst Pharmaceuticals, July 8, 2026, reporting the stockholder vote: https://www.sec.gov/Archives/edgar/data/1369568/000119312526298739/d109692d8k.htm
• Catalyst investor-relations SEC filings index: https://ir.catalystpharma.com/financial-information/sec-filings/default.aspx